Arintra
-76%
est. 2Y upside i
Medical coding automation
Rank
#3553
Sector
Healthcare IT
Est. Liquidity
~4Y
Data Quality
Data: MediumThe equity upside is very negative over 2 years due to a low growth rate (7% YoY), high valuation (7.4x ARR), critical incumbent threats, and likely dilutive fundraising.
Last updated: July 3, 2026
Even at a 5x forward revenue multiple, projected revenues of $17.7M yield an exit value of $88.6M, below the $120M entry. Dilution of 20% exacerbates losses.
At a 4x multiple, exit value of $70.9M, far below entry. Low growth and fierce competition compress multiples.
At a 2x multiple, exit value of $35.4M barely above total funding, with severe dilution and preference overhang.
Preference Stack Risk
highFunding Intensity
1790%Total funding of $21.5M represents 17.9% of current valuation, creating high preference overhang.
Dilution Risk
highWith only $21.5M total funding and 138 employees, a dilutive raise within 24 months is highly probable.
Secondary Liquidity
noneNo secondary market transactions reported; liquidity limited to M&A or IPO.
Questions to Ask at the Interview
Strategic questions based on Arintra's data — designed to show you've done your homework.
- 1
“How do you plan to overcome the critical threat from EHR vendors embedding coding features?”
- 2
“What is the path to profitability given low growth and high burn?”
- 3
“How does the equity compensation structure account for the high preference overhang?”
Community
Valuation Sentiment
Our model estimates -76% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.